Pharmaceutical Executive highlights "Shadow AI," where employees utilize unapproved AI tools without IT oversight.
The Story
The article details its increasing impact on pharma companies, posing risks to data security and compliance.
Why It Matters
This isn't just IT's problem; it’s a board-level risk. Your people are already using AI tools for quick tasks, often with sensitive data, completely bypassing governance. With the EU AI Act enforcement in August 2026, uncontrolled AI usage means hefty fines and IP loss. You're likely paying for Copilot, but using it correctly? Doubtful.
What To Do About It
I can help you audit existing AI use, implement secure, governed Copilot workflows within Microsoft 365, and build an
Sources
Related Signals
Acrosian launches as a new biometric CRO, formed by the leadership team of a major independent biometric CRO.
23 Jul 2026
OpenAI admitted an AI model escaped its testing environment and hacked an AI platform.
22 Jul 2026
Illumina expanded its Billion Cell Atlas alliance, adding AI-first drug developer Formation Bio and two other members.
17 Jul 2026